Dyslipidaemia is a global health concern that affects more and more people every day. Western lifestyle is the main cause of the unhealthy high levels of LDL cholesterol (LDL-C) and triglycerides (TGs), which increase the risk of cardiovascular disease (CVD). According to the most recent report by WHO, 31% of all global deaths are caused by CVD.
Together with the concern about dyslipidaemia among physicians there is also a trend, especially among general practitioners, to demedicalise and to encourage patients to engage in the control of their raised cholesterol and TGs levels. In addition, patients have an increasing preference for more natural, alternative solutions.
Within this scenario, AB-Biotics offers a novel solution - AB-LIFE, a powerful tool to combine with healthy lifestyle and education to increase patient engagement in the nutritional therapy for dyslipidaemia. It has been shown to reduce LDL-C by up to 14.6% and TG levels by up to 16.2% in just three months. AB-LIFE probiotic formula consists of three Lactobacillus plantarum strains - CECT7527, CECT7528 and CECT7529 - acting synergistically to reduce the endogenous source of cholesterol, which represents around 75% of the total source of blood cholesterol. Then , unlike other alternatives, AB-LIFE maintains efficacy in low-cholesterol diets by reducing endogenous cholesterol.
Foods and beverages have been supplemented with sterols and other compounds that only target exogenous cholesterol obtained from the diet. This is why AB-LIFE represents a breakthrough in the dyslipidaemia approach.
This probiotic affects exogenous sources of cholesterol through an exclusive mechanism of action - modulation of the enterohepatic cholesterol cycle. The three strains of AB-LIFE reduce intestinal reabsorption of bile salts thanks to their high bile salt hydrolase (BSH) activity.
Basically, BSH activity deconjugates the bile salts while they remain in the gut. Then, less deconjugated bile acids are reabsorbed into the bloodstream. This reduces the amount of recirculated bile salts to the liver, thus forcing the liver to pull out cholesterol from the blood in order to synthesise bile salts de novo, thus reducing levels of LDL-C in the blood.
The deconjugated bile acids can be metabolised into secondary bile acids, which in turn bind to the TGR5 receptors in various tissues. This induces an increment of caloric expenditure, especially in muscle and adipose tissue, causing a reduction of circulating TGs in the bloodstream.
AB-LIFE's mechanism of action opens up a new window of possibilities yet to be widely used. It could be used in functional dairy products to obtain meaningful reductions of LDL-C. Unlike sterols, AB-LIFE can be ingested at any time of the day; it does not need to be taken with a meal to be effective.
Moreover, the addition of AB-LIFE will cause the product not only to reduce cholesterol but also decrease the circulating TG levels, which could potentially be used to treat a fatty liver.